Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3112-3124
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3112
Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects
Seow Chong Lee, Hwee Tong Tan, Maxey Ching Ming Chung
Seow Chong Lee, Hwee Tong Tan, Maxey Ching Ming Chung, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Maxey Ching Ming Chung, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore
Author contributions: Lee SC, Tan HT and Chung MCM contributed to this paper.
Supported by The National Medical Research Council (NMRC), Singapore (NMRC grant 1259/2010), and a National University of Singapore President’s Graduate Fellowship to Lee SC
Correspondence to: Maxey Ching Ming Chung, Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore. bchcm@nus.edu.sg
Telephone: +65-65163252 Fax: +65-67791453
Received: September 30, 2013
Revised: December 3, 2013
Accepted: January 2, 2014
Published online: March 28, 2014
Processing time: 177 Days and 21.5 Hours
Core Tip

Core tip: Hepatocellular carcinoma (HCC) patients have poor prognosis, largely due to the high incidence of recurrence. There is an urgent need for prognostic biomarkers to stratify patients with higher risk of recurrence to aid in clinical management. This review surveys the use of transcriptomics, proteomics and metabolomics in identifying prognostic biomarkers for HCC recurrence. Integration of data from various omics field allow for understanding of major pathways that were dysregulated in HCC recurrence, which could pave the way for development of personalized medicine for management of HCC recurrence.